About mirum pharmaceuticals inc - MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
MIRM At a Glance
Mirum Pharmaceuticals, Inc.
989 East Hillsdale Boulevard
Foster City, California 94404
| Phone | 1-650-667-4085 | Revenue | 521.31M | |
| Industry | Pharmaceuticals: Major | Net Income | -23,363,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 54.743% | |
| Fiscal Year-end | 12 / 2026 | Employees | 372 | |
| View SEC Filings |
MIRM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.606 |
| Price to Book Ratio | 13.027 |
| Price to Cash Flow Ratio | 71.03 |
| Enterprise Value to EBITDA | 1,850.706 |
| Enterprise Value to Sales | 7.484 |
| Total Debt to Enterprise Value | 0.082 |
MIRM Efficiency
| Revenue/Employee | 1,401,376.344 |
| Income Per Employee | -62,803.763 |
| Receivables Turnover | 4.227 |
| Total Asset Turnover | 0.689 |
MIRM Liquidity
| Current Ratio | 2.671 |
| Quick Ratio | 2.55 |
| Cash Ratio | 1.863 |
MIRM Profitability
| Gross Margin | 80.706 |
| Operating Margin | -4.246 |
| Pretax Margin | -4.11 |
| Net Margin | -4.482 |
| Return on Assets | -3.087 |
| Return on Equity | -8.648 |
| Return on Total Capital | -3.684 |
| Return on Invested Capital | -3.981 |
MIRM Capital Structure
| Total Debt to Total Equity | 101.513 |
| Total Debt to Total Capital | 50.375 |
| Total Debt to Total Assets | 37.903 |
| Long-Term Debt to Equity | 100.834 |
| Long-Term Debt to Total Capital | 50.038 |